Impact of CD105 Flow-Cytometric Expression on Childhood B-Acute Lymphoblastic Leukemia

References

• Terwilliger T, Abdul-Hay MJ. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 2017;7(6):e577–e577. doi:10.1038/bcj.2017.53
   PubMed Web of Science ®Google Scholar
• Paul S, Kantarjian H, Jabbour EJ. Adult acute lymphoblastic leukemia. Mayo Clin Proc. 2016;91(11):1645–1666. doi:10.1016/j.mayocp.2016.09.010
   PubMed Web of Science ®Google Scholar
• Tzortzatou-Stathopoulou F, Papadopoulou AL, Moschovi M, Botsonis A, Tsangaris GT. The low relapse rate in children with acute lymphoblastic leukemia after risk –directed therapy. J Pediatr Hematol Oncol. 2001;23(9):591–597. doi:10.1097/00043426-200112000-00008
   Web of Science ®Google Scholar
• Rashed WM, Hamza MM, Matboli M, Salem SI. MicroRNA as a prognostic biomarker for survival in childhood acute lymphoblastic leukemia: a systematic review. Cancer Metastasis. 2019;38(4):771–782. doi:10.1007/s10555-019-09826-0
   PubMed Web of Science ®Google Scholar
• Xu B, Hu C, Miao XD, et al. Immunophenotyping of 106 adult patients with acute leukemia by flow cytometry. Di Yi Jun Yi Da Xue Xue Bao. 2003;23(10):1043.
   Google Scholar
• Khoury H, Dalal BI, Nevill TJ. Acute myelogenous leukemia with t (8; 21)–identification of a specific immunophenotype. Leuk Lymphoma. 2003;44(10):1713–1718. doi:10.1080/1042819031000116698
   PubMed Web of Science ®Google Scholar
• Minhajat R, Mori D, Yamasaki F, Sugita Y, Satoh T, Tokunaga O. Organ-specific endoglin (CD105) expression in the angiogenesis of human cancers. Pathol Int. 2006;56(12):717–723. doi:10.1111/j.1440-1827.2006.02037.x
   Web of Science ®Google Scholar
• Fonsatti E, Vecchio LD, Altomonte M, et al. Endoglin: an accessory component of the TGF‐β‐binding receptor‐complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies. J Cell Physiol. 2001;188(1):1–7. doi:10.1002/jcp.1095
   Web of Science ®Google Scholar
• Dallas NA, Samuel S, Xia L, et al. Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. Clin Cancer Res. 2008;14(7):1931–1937. doi:10.1158/1078-0432.CCR-07-4478
   PubMed Web of Science ®Google Scholar
• Brum ST, Demasi AP, Stelini RF, Cintra ML, de Araujo VC, Soares AB. Endoglin is highly expressed in human mast cells. Appl Immunohistochem Mol Morphol. 2019;27(8):613–617. doi:10.1097/PAI.0000000000000668
   Google Scholar
• McAllister KA, Grogg KM, Johnson DW, et al. Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet. 1994;8(4):345–351. doi:10.1038/ng1294-345
   PubMed Web of Science ®Google Scholar
• Bühring HJ, Müller CA, Letarte M, et al. Endoglin is expressed on a subpopulation of immature erythroid cells of normal human bone marrow. Leukemia. 1991;5(10):841.
   Web of Science ®Google Scholar
• Rokhlin OW, Cohen MB, Kubagawa H, et al. Differential expression of endoglin on fetal and adult hematopoietic cells in human bone marrow. J Immunol. 1995;154(9):4456–4465.
   Web of Science ®Google Scholar
• Borges L, Oliveira VK, Baik J, Bendall SC, Perlingeiro RC. Serial transplantation reveals a critical role for endoglin in hematopoietic stem cell quiescence. Blood. 2019;133(7):688–696. doi:10.1182/blood-2018-09-874677
   Web of Science ®Google Scholar
• Della Porta MG, Malcovati L, Invernizzi R, et al. Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome. Leukemia. 2006;20(4):549–555. doi:10.1038/sj.leu.2404142
   Web of Science ®Google Scholar
• Cosimato V, Scalia G, Raia M, et al. Surface endoglin (CD105) expression on acute leukemia blast cells: an extensive flow cytometry study of 1002 patients. Leuk Lymphoma. 2018;59(9):2242–2245. doi:10.1080/10428194.2017.1416366
   PubMed Web of Science ®Google Scholar
• Poręba M, Jaźwiec B, Poręba R, Kuliczkowski K. Expression of CD105 antigen in patients with acute leukemia, malignant lymphoma, and multiple myeloma in active phase of the disease. Adv Clin Exp Med. 2006;15(6):1023–1028.
   Google Scholar
• Chakhachiro ZI, Zuo Z, Aladily TN, et al. CD105 (endoglin) is highly overexpressed in a subset of cases of acute myeloid leukemias. Am J Clin Pathol. 2013;140(3):370–378. doi:10.1309/AJCPG8XH7ZONAKXK
   Web of Science ®Google Scholar
• Kauer J, Schwartz K, Tandler C, et al. CD105 (Endoglin) as negative prognostic factor in AML. Sci Rep. 2019;9(1):1. doi:10.1038/s41598-019-54767-x
   Web of Science ®Google Scholar
• Dourado K, Baik J, Oliveira VK, et al. Endoglin: a novel target for therapeutic intervention in acute leukemias revealed in xenograft mouse models. Blood. 2017;129(18):2526–2536. doi:10.1182/blood-2017-01-763581
   PubMed Web of Science ®Google Scholar
• Borowitz MJ, Devidas M, Hunger SP, et al.; Children’s Oncology Group. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children’s Oncology Group study. Blood. 2008;111(12):5477–5485. PMID: 18388178; PMCID: PMC2424148. doi:10.1182/blood-2008-01-132837.
   PubMed Web of Science ®Google Scholar
• Pui CH, Relling MV, Sandlund JT, Downing JR, Campana D, Evans WE. Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemia. Ann Hematol. 2004;83:S124–6. doi:10.1007/s00277-004-0850-2
   Web of Science ®Google Scholar
• Dawson BD, Trapp RG. Basic & Clinical Biostatistics. 3rd ed. New York, NY: Medical Publication Division, Lange Medical Book/McGraw-Hill; 2001:161–218.
   Google Scholar
• Xu P, Wang M, Jiang Y, Ouyang J, Chen B. The association between hypoxia inducible factor 1α and multidrug resistance of acute myeloid leukemia. Transl Cancer Res. 2017;6(1):198–205. doi:10.21037/tcr.2017.01.10
   Web of Science ®Google Scholar
• Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukemia. Lancet. 2013;381(9881):1943–1955. doi:10.1016/S0140-6736(12)62187-4
   PubMed Web of Science ®Google Scholar
• Dias A, Kenderian SJ, Westin GF, Litzow MR. Novel therapeutic strategies in acute lymphoblastic leukemia. Curr Hematol Malig Rep. 2016;11(4):253–264. doi:10.1007/s11899-016-0326-1
   PubMed Web of Science ®Google Scholar
• Farhadfar N, Litzow MR. New monoclonal antibodies for the treatment of acute lymphoblastic leukemia. Leuk Res. 2016;49:13–21. doi:10.1016/j.leukres.2016.07.009
   PubMed Web of Science ®Google Scholar